-

Croma Skincare – Where Science Meets Skin

LEOBENDORF, Austria--(BUSINESS WIRE)--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.

Building on 50 years of experience in hyaluronic acid, Croma Pharma developed this skincare range to bridge the gap between in-clinic treatments and at-home care. The result is a streamlined portfolio that supports key skin needs such as hydration, glow, balance, and protection.

The formulations combine high-performance actives including niacinamide, peptides, hyaluronic acid, and plant stem cells with lightweight, fast-absorbing textures that strengthen the skin barrier and enhance overall skin health.

Hero products include:

  • THE GLOW - a 20% stabilized vitamin C serum for radiance, antioxidant protection, and a more even complexion
  • THE EVERYDAY - balancing daily care for healthy-looking skin
  • THE SHIELD - protective hydration for urban lifestyles
  • THE SUNKISSED - mineral sun protection designed for daily wear

All products are vegan, dermatologically tested, and free from microplastics, reflecting Croma's commitment to quality, safety, and responsible formulation.

Croma Skincare is available via the official webshop and selected partners, as well as through local Croma Pharma representatives.

https://www.cromaskincareshop.com

About Croma

CROMA-PHARMA GmbH is a global player and challenger in the dynamically growing minimally invasive aesthetics market, and one of Europe’s leading manufacturers of premium-quality hyaluronic acid (HA) syringes. Founded in 1976 by the pharmacist couple Gerhard and Karin Prinz, Croma has evolved from a family pharmacy into a globally operating Austrian company headquartered near Vienna, where it also runs its state-of-the-art, fully automated HA manufacturing plant. The company employs around 400 people, making its products available in over 80 countries worldwide. Croma offers a comprehensive and innovative aesthetics portfolio covering all key treatment categories in minimally invasive aesthetic medicine. Its range includes botulinum toxin, a broad selection of hyaluronic acid fillers, lifting threads (PDO threads), polynucleotide injectables, HA skin booster, skincare, as well as autologous PRP I Fluid‑PRF medical device. With this full‑face approach, Croma provides aesthetic professionals and their patients with safe, effective, and reliable solutions from a single trusted source. In 2025, the company surpassed 110 million syringes produced, further strengthening its position as one of Europe’s leading HA manufacturers. Building on its heritage in orthopedics and ophthalmology, Croma is re-entering the orthopedics market in 2026, marking a strategic expansion beyond aesthetics and reinforcing its roots in medical applications.

Contacts

Press contact:
CROMA-PHARMA GmbH
Victoria Szafraniec
Global Digital Media & PR Manager
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846 868 494
Mail: victoria.szafraniec@croma.at
Web: www.cromapharma.com

CROMA-PHARMA GmbH



Contacts

Press contact:
CROMA-PHARMA GmbH
Victoria Szafraniec
Global Digital Media & PR Manager
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846 868 494
Mail: victoria.szafraniec@croma.at
Web: www.cromapharma.com

Social Media Profiles
More News From CROMA-PHARMA GmbH

Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States

LEOBENDORF, Austria--(BUSINESS WIRE)--Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of...

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics....

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of...
Back to Newsroom